Skip to content
value.today

Yarrow Bioscience, Inc.

YARW
$307 Mmarket cap on Oct 28, 2026
Compare
World rank
#14,688
Revenue
$1 M
For year ending December-2025
Net income
$-26 M
-4645.6% margin
SEC filing
Employees
10
As of December 31, 2025
value.today research

Yarrow Bioscience, Inc. in brief

Yarrow Bioscience, Inc. is a listed company in the Biotechnology industry, based in California, USA. It was founded in 2011. Its market value was $307 M on 28 October 2026, which makes it the 14,688th largest listed company in the world and the 2,862nd largest in the USA on this site. In the year to December 2025 it had sales of $1 M and a net loss of $26 M. It employs about 10 people. Its largest product and service lines by sales in 2025 were Royalty revenues (95%). Its shares trade under the symbol YARW (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Yarrow Bioscience, Inc.

We are a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat inflammatory and immune-mediated conditions with high unmet need.

We have exclusive worldwide rights to research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain inhibitors for the treatment of any disease, disorder or condition in humans, which we licensed from Tay Therapeutics Ltd., formerly known as In4Derm Ltd. BET proteins are epigenetic enablers of transcription that regulate the expression of specific genes. Each BET protein consists of two bromodomains and one end terminal domain. Through our transaction with Tay, we obtained access to a library of new small molecule BET inhibitor compounds including those that inhibit both BD1 and BD2 and that selectively inhibit BD2. We initially focused our development efforts with these molecules on immune-mediated inflammatory diseases, which are not being targeted by current BET inhibitors in development.

Yarrow Bioscience, Inc. timeline

8 events, 2011–2026
  1. 2011
  2. 🏁
    · approximate
    Founded
  3. 2013
  4. ✎
    Renamed Menlo Therapeutics, Inc.
    Formerly Tigercat Pharma, Inc..
  5. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  6. 2018
  7. 🔔
    · approximate
    Initial public offering on Nasdaq
  8. 🔔
    Initial public offering as Menlo Therapeutics, Inc.
    Final prospectus filed with the SEC on 26 January 2018; shares registered for exchange trading on 19 January 2018.
  9. 2020
  10. 💰
    Record revenue of $21 million
    FY2020, the highest of the 8 years on record.
  11. ✎
    Renamed VYNE Therapeutics Inc.
    Formerly Menlo Therapeutics, Inc..
  12. 2026
  13. ✎
    Renamed Yarrow Bioscience, Inc.
    Formerly VYNE Therapeutics Inc..

Events of Yarrow Bioscience, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$83 M$166 M$248 M$331 M

World rank over time

▲ up 378 places since 2026
2026-10-14: #15101#15,10120262026-10-28: #14723#14,7232026

Rank in USA: #2,921 (Oct 2026) · #2,866 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
625.6×
Price / book
11.0×
Free cash flow yield
-10.8%
Net margin (TTM)
-3816.3%
Operating margin
-5219.3%
Return on equity
-67.4%
Liabilities / assets
8.0%
Net debt
$-24M
Revenue growth
+14.0%
R&D / revenue
3375.4%
Revenue per employee
$57 K
Profit per employee
$-2.6 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $11M, net income $-74M$11MFY18Fiscal year ending Dec 2019: revenue $0M, net income $-95M$0MFY19Fiscal year ending Dec 2020: revenue $21M, net income $-256M$21MFY20Fiscal year ending Dec 2021: revenue $1M, net income $-73M$1MFY21Fiscal year ending Dec 2022: revenue $0M, net income $-23M$0MFY22Fiscal year ending Dec 2023: revenue $0M, net income $-28M$0MFY23Fiscal year ending Dec 2024: revenue $1M, net income $-40M$1MFY24Fiscal year ending Dec 2025: revenue $1M, net income $-26M$1MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$1M+14.0%$-30M$-26M-4645.6%
Dec 2024$1M+19.0%$-44M$-40M-7966.0%
Dec 2023$0M-12.5%$-29M$-28M-6773.8%
Dec 2022$0M-48.4%$-34M$-23M-4835.4%
Dec 2021$1M-95.6%$-39M$-73M-7884.9%
Dec 2020$21M+4670.5%$-253M$-256M-1217.6%
Dec 2019$0M-95.9%$-96M$-95M-21631.8%
Dec 2018$11M—$-75M$-74M-697.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-33M$0M$-33M$-0.62—
Dec 2024$-34M$0M$-34M$-0.93—
Dec 2023$-25M$0M$-25M$-2.78—
Dec 2022$-29M——$-7.28—
Dec 2021$-56M$0M$-56M$-25.64—
Dec 2020$-137M$0M$-137M$7.88—
Dec 2019$-73M$1M$-74M$11.22—
Dec 2018$-69M$1M$-69M$11.47—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$0M
Net income, trailing 12 months
$-19M
RevenueNet income
Three months to Jun 2024: revenue $0M, net income $-9M$0MJun ’24Three months to Sep 2024: revenue $0M, net income $-12M$0MSep ’24Three months to Dec 2024 (from the annual report): revenue $0M, net income $-12M$0MDec ’24Three months to Mar 2025: revenue $0M, net income $-9M$0MMar ’25Three months to Jun 2025: revenue $0M, net income $-6M$0MJun ’25Three months to Mar 2026: revenue $0M, net income $-4M$0MMar ’26Three months to Jun 2026: revenue $0M, net income $-3M$0MJun ’26Three months to Sep 2026: revenue —, net income $-10M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-10M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Yarrow Bioscience, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$1 M
Operating income
$-30 M
Net income
$-26 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$30 M
Total liabilities
$2 M
Total equity
$28 M

As of December-2025

Top 49 institutional investors in Yarrow Bioscience, Inc.#

As of Sep 30, 2026
49 institutions held 9.4 M shares (about 61.8% of the shares outstanding) on Sep 30, 2026. The ten largest hold 42.9%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Yarrow Bioscience, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Logos Global Management LP1,026,258New6.74%$23 MNov 16, 2026
2Bellevue Group AG1,000,000New6.56%$23 MNov 16, 2026
3Perceptive Advisors LLC813,098New5.34%$18 MNov 16, 2026
4Ameriprise Financial Inc739,538New4.85%$17 MNov 16, 2026
5Siren, L.L.C.675,000New4.43%$15 MNov 12, 2026
6Spruce Street Capital LP607,382New3.99%$14 MNov 13, 2026
7venBio Partners LLC554,769New3.64%$12 MNov 16, 2026
8Soleus Capital Management, L.P.416,993New2.74%$9 MNov 16, 2026
9Vanguard Capital Management LLC368,034New2.42%$8 MNov 13, 2026
10Braidwell LP331,400New2.18%$7 MNov 16, 2026
11Driehaus Capital Management LLC305,000New2.00%$7 MNov 16, 2026
12Silverarc Capital Management, LLC301,919New1.98%$7 MNov 12, 2026
13Citadel Advisors LLC297,361New1.95%$7 MNov 16, 2026
14Janus Henderson Group Ltd.283,341—1.86%$6 MNov 16, 2026
15ADAR1 Capital Management, LLC282,996New1.86%$6 MNov 16, 2026
16Orbimed Advisors LLC266,306New1.75%$6 MNov 16, 2026
17Marshall Wace, LLP237,183New1.56%$5 MNov 13, 2026
18Squadron Capital Management LLC225,000New1.48%$5 MNov 16, 2026
19BlackRock, Inc.89,892New0.59%$2 MNov 13, 2026
20Geode Capital Management, LLC84,720New0.56%$2 MNov 6, 2026
21Morgan Stanley68,094New0.45%$2 MNov 13, 2026
22J. Goldman & Co LP55,751New0.37%$1 MNov 16, 2026
23Vanguard Fiduciary Trust Co50,629New0.33%$1 MNov 13, 2026
24Monashee Investment Management LLC40,000New0.26%$1 MNov 6, 2026
25Seven Fleet Capital Management LP40,000New0.26%$1 MNov 16, 2026
Show all 49: investors 26 to 49
Institutional investors 26 to 49 in Yarrow Bioscience, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Nantahala Capital Management, LLC39,198New0.26%$1 MNov 13, 2026
27Walleye Capital LLC33,265New0.22%$1 MNov 13, 2026
28Qube Research & Technologies Ltd23,954New0.16%$1 MNov 13, 2026
29Two Sigma Investments, LP23,811New0.16%$1 MNov 16, 2026
30Lynx1 Capital Management LP22,000New0.14%$0 MNov 16, 2026
31Northern Trust Corp18,164New0.12%$0 MNov 16, 2026
32Prelude Capital Management, LLC16,975New0.11%$0 MNov 16, 2026
33XTX Topco Ltd12,282New0.08%$0 MNov 16, 2026
34Soros Fund Management LLC12,000New0.08%$0 MNov 13, 2026
35Millennium Management LLC10,785New0.07%$0 MNov 16, 2026
36Atom Investors LP10,206New0.07%$0 MNov 16, 2026
37KVP Capital Advisors, LP10,011New0.07%$0 MNov 16, 2026
38Jump Financial, LLC9,439New0.06%$0 MNov 13, 2026
39US Bancorp \de\4,992New0.03%$0 MNov 5, 2026
40Aster Capital Management (DIFC) Ltd3,179New0.02%$0 MNov 12, 2026
41Persistent Asset Partners Ltd3,092New0.02%$0 MNov 13, 2026
42Vanguard Global Advisers, LLC3,081New0.02%$0 MNov 13, 2026
43Tower Research Capital LLC (TRC)2,076New0.01%$0 MNov 16, 2026
44UBS Group AG1,744New0.01%$0 MNov 10, 2026
45Citigroup Inc232New0.00%$0 MNov 4, 2026
46Caitong International Asset Management Co., Ltd28New0.00%$0 MOct 29, 2026
47MB, Levis & Associates, LLC20New0.00%$0 MOct 16, 2026
48Centerpoint Advisors, LLC12New0.00%$0 MNov 5, 2026
49Hurley Capital, LLC11New0.00%$0 MNov 5, 2026

Superinvestors holding Yarrow Bioscience, Inc.

1 of the well-known investors value.today follows, from their newest Form 13F.

Insider trading at Yarrow Bioscience, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
27
since
$51 K$0Nov 2023: bought $51 K (1 trades), sold $0 (0 trades)Nov 23Jan 2025: bought $44 K (1 trades), sold $0 (0 trades)Jan 25
Bought (open market)Sold (open market)Hover a month for the totals
Yarrow Bioscience, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Roderick Wong10% ownerOtherindirect-133,290——266,307Form 4
filed David DomzalskiPRESIDENT AND CEO, DirectorShares withheld for tax-79,391$0.900$71 K347,174Form 4
filed Tyler ZerondaCHIEF FINANCIAL OFFICERShares withheld for tax-22,516$0.900$20 K74,918Form 4
filed Iain StuartCHIEF SCIENTIFIC OFFICERShares withheld for tax-15,405$0.900$14 K95,944Form 4
filed Mutya HarschCHIEF LEGAL OFFICER AND GCShares withheld for tax-22,516$0.900$20 K95,918Form 4
filed David DomzalskiPRESIDENT AND CEO, DirectorShares withheld for tax-12,214$0.650$8 K426,565Form 4
filed Mutya HarschCHIEF LEGAL OFFICER AND GCShares withheld for tax-3,464$0.650$2 K118,434Form 4
filed Iain StuartCHIEF SCIENTIFIC OFFICERShares withheld for tax-2,370$0.650$2 K111,349Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Yarrow Bioscience, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
141,913
1 days to cover
Shares sold short, last 7 reportsAll stocks →

Stock splits: 1-for-50 reverse split ; 1-for-18.02 reverse split ; 1-for-4 reverse split

Fails to deliver

  • : 2 shares at $20.12
  • : 5,214 shares at $18.31
  • : 10,148 shares at $18.60
  • : 10,180 shares at $19.82
  • : 327 shares at $24.00

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Yarrow Bioscience, Inc. scorecard#

Passes 6 of the 17 checks that could be worked out: strongest in financial health (4 of 5), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median11.0×Price to book 11.0× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median625.6×Price to sales 625.6× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-10.8%Free cash flow is -10.8% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 3
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.62 vs -0.93Diluted EPS -0.62 in fiscal 2025 against -0.93 the year before (report's currency).
    • ✓Net income higher than five years earlier-$26 M-$26 M in fiscal 2025 against -$256 M in 2020.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$26 MNet income -$26 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-66.3%-66.3% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health4 of 5
    • ✓Short-term assets cover short-term liabilities12.5×Current ratio 12.50 at the end of fiscal 2025.
    • ✓Debt below equity0.0×Debt to equity 0.00 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $24 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✓Altman Z-score outside the distress zone39.33Z-score 39.33 (safe zone) for fiscal 2025.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year0.4%Diluted shares up 0.4% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Yarrow Bioscience, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Yarrow Bioscience, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue0.60.50.40.50.9r210.4r114.60.7
Cost of revenue————3.31.400——
Research and development1931161820r4451r64r2911
Selling, general and administrative———1620r904514——
General and administrative11131316——22125.23.8
Operating expenses——————76653415
Total costs and expenses3044303540r2729678——
Operating income−30−44−29−34−39r−253−96r−75r−30−14
Interest expense and finance costs———05.64.40.90——
Other non-operating income (expense)3.03.81.40.4−0.11.1r−1.4r−0.9r0.50.3
Income before tax−27−40−28−34−45r−256−95−74——
Income tax0.00.000.0−0.4−0.3−0.2r0.2r0—
Income from continuing operations−27−40−28−34−44—————
Income from discontinued operations0.3−0.0−0.611−29—————
Net income attributable to shareholders−26−40−28−23−73−256−95r−74r−29−14
Earnings per share, basic-0.62-0.93-2.78-7.28-25.64r7.8811.22r11.47r-5.69-2.82
Earnings per share, diluted-0.62-0.93-2.78-7.28-25.64r7.8811.22r11.47r-5.69-2.82
Shares, weighted average (basic)4343103.22.9r32————
Shares, weighted average (diluted)4343103.22.9r328.5r6.5r5.15.0
Balance sheet
Cash and cash equivalents100r203131425844r28r104.0r
Short-term investments5.04263001.017r874927
Receivables———0.27.6160.1—0.80
Inventory————7.37.41.4———
Other current assets0.0r2.92.72.3r4.6r4.61.6r3.33.60.6
Current assets100r649638638776r1406432
Property, plant and equipment0r0.1000.40.62.9r0.10.00.0
Right-of-use (leased) assets00.10.2001.61.7r———
Long-term investments————————3.010
Non-current assets0.4r2.51.72.53.96.54.7———
Total assets100r679841679481r1406742
Accounts payable1.5r2.71.72.46.54.83.83.32.51.5
Debt due within a year—————0————
Current liabilities72r157.59.31822r29r9.57.83.9
Long-term debt————03333———
Lease liabilities (non-current)—00.1000.90.7———
Non-current liabilities—01.40034r34———
Total liabilities72r159.09.3185664r9.61512
Retained earnings−71r−731−691−663−640−566−311r−111−59−30
Shareholders' equity−71r528931493718r92r69r−29
Total liabilities and equity100r679841679481r1406742
Shares outstanding3.0r15143.23.0r439.1r23r5.35.3
Cash-flow statement
Depreciation and amortization0.00.000.10.10.30.40.3——
Share-based compensation2.33.33.34.38.1184.9r5.3r1.50.6
Cash from operating activities−33−34−25−29−56−137−73r−69r−28r−2.3r
Capital expenditure0−0.10—0−0.1−1.1r−0.6r−0.0−0.0
Cash from investing activities3723−57161.08942r−12r−15r−38r
Debt repaid———0−360————
Shares issued———1.576621491——
Cash from financing activities−0.1−0.1821.7406248r92r490
Exchange-rate effect on cash————00.00.0−0.0——
Change in cash4.1−11−0.3———−19396.2−40
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Yarrow Bioscience, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Royalty revenues$1 M95%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Events at Yarrow Bioscience, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Change in control 2 · Acquisition or sale completed 1 · Directors and officers 4 · Material agreement 4 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 11

Yarrow Bioscience, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreement8-K
Results announced8-K/A
Change in controlAcquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changedResults announced8-K
Shareholder vote8-K
Delisting notice8-K
Material agreement8-K
Change in controlDirectors and officersMaterial agreementUnregistered share sale8-K
Shareholder vote8-K
Results announced8-K
Delisting notice8-K
Directors and officersResults announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Yarrow Bioscience, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2023$88 MPrivate placement after listing$50 to $250 million19equity, optionsSEC
Jul 2017$51 MNo. 1$50 to $250 million11equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Yarrow Bioscience, Inc. compares in Biotechnology

  • Market cap$307 M · higher than 51% of 726
  • Revenue$1 M · higher than 22% of 647
  • Revenue growth14.0% · higher than 57% of 438
  • Price / sales625.6× · lower than 1% of 339
  • Price / book11.0× · lower than 14% of 534
  • FCF yield-10.8% · higher than 55% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Yarrow Bioscience, Inc.🇺🇸$307 M——+14.0%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Yarrow Bioscience, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Yarrow Bioscience, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Yarrow Bioscience, Inc.? Suggest a correction